The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
See one reviewer saying he had more success with the Eroxon blue pills. (Shrug)
Did like one suggestion by someone on here saying it would be better to sell it in a pump action bottle. The little tubes are a bit fiddley, especially trying to get that little silver foil cover off.
And the price breathtaking... More than £6 a time!
It is good to see how Eroxon is performing on Amazon, however the reviews are poor to put it mildly .
Eroxon now up to number 47 on Amazon's Health & Personal Care Best Sellers list......
https://www.amazon.co.uk/Best-Sellers-Health-Personal-Care/zgbs/drugstore/ref=zg_bsms_tab
Number 7 on the Movers and Shakers list with sales up 100%......
https://www.amazon.co.uk/gp/movers-and-shakers/drugstore/ref=zg_bs_tab
Number 2 in Male Condoms list......
https://www.amazon.co.uk/gp/bestsellers/drugstore/2758342031/ref=pd_zg_hrsr_drugstore
Was watching Britain’s most expensive homes on channel 4 this eve and when adverts came on included an advert for Eroxon.
We are a serious player in the ED market now and with a low market cap the breakout numbers look very impressive.
I guess we shouldn’t be surprised that the latest RNS did little to boost SP, when Kingdom of SA has a population of 36 million c.f. USA 330 million and FDA approval plus Haleon partnership also did little to improve SP. We’re a few weeks away from release of interim results, which should be outstanding if fire side chat is anything to go by. I expect to see the SP tick up as we approach results day and really hoping for a major surge once real profits can be seen. My old Volvo’s got 180, 000 on the clock and needs updating!
Saw the ad on TV last night and thought isn't that FUM. And there was the news this morning. Hope things get moving forward you guys...
Expected a bit more excitement here.. rns out
There was a mining share that had the same RNS problem a week ago. Appeared on stock exchange but still not on any/most of the syndicated sites like here.
It is only a matter of time before this SP explodes . Saudi market should be huge
With Saudi men having up to four wives, the mind boggles at the sales potential there.
Eroxon has reached number 113 in "Health & Personal Care" (was around 1000 a week ago) and that is a HUGE sector, all health related products of every genre.....would be great to make the top 100.
And now number 2 in "Male Condoms"!
https://www.amazon.co.uk/gp/bestsellers/drugstore/2758342031/ref=pd_zg_hrsr_drugstore
With the money the Saudis have they will just buy it for the hell of it….. well done to the BOD …. This is all coming together
Forgive the pun.
Great progress…. And I see this morning boots are still selling over 100 in last 24 hrs…. At some point this has to explode
It's on the london stock exchange site.just an lse glitch in supply feed i imagine.
I had an email from FUM, about this approval at 7.05, but no RNS here?
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology, today announces that its distribution partner Labatec Pharma ("Labatec") has received regulatory approval for MED3000, Futura's innovative topical, gel-based Erectile Dysfunction ("ED") treatment, in the Kingdom of Saudi Arabia.
Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon®, with initial launch planned in Q4 2023. The manufacturing of Eroxon for the launch has been completed and it will be supported by a full marketing campaign. Saudi Arabia is one of the top ten ED markets in the world by value1, with a reported 10.45%2 of married males experiencing ED. Labatec will hold a launch symposium showcasing Eroxon at the 20th Urological Association of Asia Congress 2023, which is being held from 28 September to 1 October in conjunction with the 12th Emirates International Urological conference in Dubai, United Arab Emirates.
Futura is establishing a growing network of licencing and distribution partners and continues to strengthen its position, with regulatory approval having now been granted in six Middle Eastern countries, including the Kingdom of Saudi Arabia and the United Arab Emirates. Regulatory approval in the Kingdom of Saudi Arabia closely follows Futura's recent European and UK launch of Eroxon and the FDA's approval of MED3000 in the USA as the first clinically proven gel for the treatment of ED available without a doctor's prescription.
James Barder, Chief Executive Officer of Futura said: "Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market. Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes. This approval comes at a pivotal time for the Company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network."
Our new US partners are selling off major but "non core" brands... which makes me think they see Eroxon as a potentially core brand. Which is nice.
"Haleon wants to sell non-core brands in order to drive a more focused portfolio and pay down debt."
https://www.morningstar.co.uk/uk/news/AN_1691392345080869100/press-inflexion-among-firms-looking-to-buy-haleons-nicotine-business.aspx
Yes Deal did fall through! But BOD are not going to give away for single digits to anyone IMO when they struck a deal for 50/50! Time will tell we should get an idea from the financials later in the year. Nothing is going to shift the SP until we know what profits FUM are receiving per packet even if we know quantity sold!!!!
Probably why it’s still not on sale in China where there are between 175 to 200 mill sufferers. The market cap would be much higher if they had gotten approval which surely wouldn’t take 2 years when no drugs are involved.
My understanding and i could be wrong is that the Chinese deal fell through as they did not come up with the cash. An email to the company would confirm or not
Https://www.trinitydelta.org/research-notes/commercialisation-deal-for-china-and-se-asia/
Dosanddonts, could you provide the link to your post please? Much appreciated
This was the deal signed with Asia, people are talking about single figures but can’t see that based on a 50/50 profits deal!
Futura Medical has struck an innovative deal with Atlantis Group to market its MED3000 topical gel for erectile dysfunction throughout China and South East Asia. Atlantis, and its associated companies, will fund any registration studies and commercialisation costs in the region, with the resulting profits being split 50:50. Atlantic will also invest £2.0m in Futura Medical through £1.5m as Convertible Loan Notes and £0.5m in warrants, with a conversion price of 20p and exercise price of 22p respectively. The collaboration addresses market access to the largest target population for MED3000. Updating our model to reflect this deal, our new valuation is £181.5m, equivalent to 73.1p per share (71.3p fully diluted), from £153.8m, 60.9p a share, previously.